CA2685553C - Peptide imaging agents - Google Patents

Peptide imaging agents Download PDF

Info

Publication number
CA2685553C
CA2685553C CA2685553A CA2685553A CA2685553C CA 2685553 C CA2685553 C CA 2685553C CA 2685553 A CA2685553 A CA 2685553A CA 2685553 A CA2685553 A CA 2685553A CA 2685553 C CA2685553 C CA 2685553C
Authority
CA
Canada
Prior art keywords
gly
cmbp
imaging agent
cys
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2685553A
Other languages
English (en)
French (fr)
Other versions
CA2685553A1 (en
Inventor
Edvin Wilhelm Johannesen
Alan Cuthbertson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
GE Healthcare AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0709441A external-priority patent/GB0709441D0/en
Priority claimed from GB0715682A external-priority patent/GB0715682D0/en
Application filed by GE Healthcare AS filed Critical GE Healthcare AS
Publication of CA2685553A1 publication Critical patent/CA2685553A1/en
Application granted granted Critical
Publication of CA2685553C publication Critical patent/CA2685553C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Solid State Image Pick-Up Elements (AREA)
CA2685553A 2007-05-16 2008-05-16 Peptide imaging agents Active CA2685553C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0709441A GB0709441D0 (en) 2007-05-16 2007-05-16 Peptide imaging agents
GB0709441.0 2007-05-16
GB0715682A GB0715682D0 (en) 2007-08-13 2007-08-13 Peptide imaging agents
GB0715682.1 2007-08-13
PCT/GB2008/001696 WO2008139207A2 (en) 2007-05-16 2008-05-16 Labelled hgf binding peptides for imaging

Publications (2)

Publication Number Publication Date
CA2685553A1 CA2685553A1 (en) 2008-11-20
CA2685553C true CA2685553C (en) 2017-03-28

Family

ID=39743846

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2685553A Active CA2685553C (en) 2007-05-16 2008-05-16 Peptide imaging agents

Country Status (17)

Country Link
US (1) US8529874B2 (https=)
EP (1) EP2146749B1 (https=)
JP (1) JP2010526859A (https=)
KR (2) KR101578225B1 (https=)
CN (1) CN101848734B (https=)
AT (1) ATE551073T1 (https=)
AU (1) AU2008249821B2 (https=)
BR (1) BRPI0811210B1 (https=)
CA (1) CA2685553C (https=)
ES (1) ES2385066T3 (https=)
IL (1) IL201778A0 (https=)
MX (1) MX2009012386A (https=)
NZ (1) NZ581160A (https=)
PL (1) PL2146749T3 (https=)
RU (2) RU2473361C9 (https=)
WO (1) WO2008139207A2 (https=)
ZA (1) ZA200908016B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100017102A (ko) * 2007-05-16 2010-02-16 지이 헬스케어 에이에스 광학 조영제
GB0718967D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0918321D0 (en) 2009-10-20 2009-12-02 Ge Healthcare As Cyclic peptide synthesis
GB201010878D0 (en) 2010-06-29 2010-08-11 Ge Healthcare As Dye compositiion and dye syntheses
CN103052690A (zh) * 2010-06-29 2013-04-17 通用电气医疗集团股份有限公司 染料组合物和染料合成
GB201013808D0 (en) * 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
WO2012048063A2 (en) * 2010-10-06 2012-04-12 Emd Millipore Corporation Cyanine compounds, conjugates and method of use
CN103687627A (zh) 2011-03-01 2014-03-26 通用电气健康护理有限公司 作为pet示踪剂的放射性标记的奥曲肽酸类似物
GB201103696D0 (en) * 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
DE102011118029A1 (de) 2011-06-20 2012-12-20 Universität Leipzig Modifizierte antibiotische Peptide mit variabler systemischer Freisetzung
GB201116733D0 (en) 2011-09-28 2011-11-09 Ge Healthcare As Peptide margin imaging agents
GB201116862D0 (en) 2011-09-30 2011-11-09 Ge Healthcare As Infusion imaging method
GB201121914D0 (en) * 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
US10046068B2 (en) * 2013-03-15 2018-08-14 Arizona Board Of Regents On Behalf Of Arizona State University Saccharide conjugates
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
CN105111773B (zh) * 2015-08-19 2017-06-27 大连理工大学 一类氨基菁类荧光染料及其制备方法和应用
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
CN112129736B (zh) * 2020-09-22 2022-08-02 四川大学华西医院 粘蛋白和循环肿瘤细胞的均相可视化/荧光poct检测方法
US20240368406A1 (en) * 2021-06-07 2024-11-07 Surgvision Gmbh Stable liquid phantom for near-infrared fluorescence verification
TW202404643A (zh) 2022-04-20 2024-02-01 大陸商同宜醫藥（蘇州）有限公司 化合物及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039894A2 (en) 2002-05-10 2004-05-13 Carnegie Mellon University Chiral indole intermediates and their fluorescent cyanine dyes containing functional groups
GB0223249D0 (en) * 2002-10-08 2002-11-13 Amersham Plc Improved imaging agents
WO2004075032A2 (en) * 2003-02-19 2004-09-02 Sicel Technologies Inc. In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes
PT2949658T (pt) * 2003-03-03 2018-10-18 Bracco Suisse Sa Péptidos que ligam especificamente o recetor de hgf (cmet) e utilizações dos mesmos
NO20034350D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av kolorektal kreft
JP4943156B2 (ja) * 2003-10-31 2012-05-30 ジーイー・ヘルスケア・ユーケイ・リミテッド シアニン色素標識用試薬
EP1699495A2 (en) 2003-11-06 2006-09-13 Amersham Health AS Conjugates of angiotensin ii and an imaging moiety
NO20035682D0 (no) 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av ösofagkreft og Barretts ösofag
CN101272808B (zh) * 2005-01-06 2012-03-21 通用电气医疗集团股份有限公司 光学成像
WO2006078914A1 (en) * 2005-01-21 2006-07-27 Washington University In St. Louis Compounds having rd targeting motifs
GB0502277D0 (en) 2005-02-04 2005-03-09 Amersham Plc Novel imaging agents
ATE502048T1 (de) * 2005-04-22 2011-04-15 Univ Washington Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
NO20053354D0 (no) * 2005-07-11 2005-07-11 Amersham Health As Optical imaging contrast agent.

Also Published As

Publication number Publication date
WO2008139207A2 (en) 2008-11-20
NZ581160A (en) 2012-05-25
AU2008249821A1 (en) 2008-11-20
US8529874B2 (en) 2013-09-10
PL2146749T3 (pl) 2012-09-28
AU2008249821B2 (en) 2013-08-22
RU2009140478A (ru) 2011-06-27
JP2010526859A (ja) 2010-08-05
BRPI0811210A2 (pt) 2014-11-11
CA2685553A1 (en) 2008-11-20
RU2475266C2 (ru) 2013-02-20
KR20100016543A (ko) 2010-02-12
RU2473361C2 (ru) 2013-01-27
RU2009140475A (ru) 2011-06-27
ES2385066T3 (es) 2012-07-17
RU2473361C9 (ru) 2013-06-20
KR101578225B1 (ko) 2015-12-17
EP2146749B1 (en) 2012-03-28
ATE551073T1 (de) 2012-04-15
KR20150017387A (ko) 2015-02-16
MX2009012386A (es) 2009-12-03
CN101848734A (zh) 2010-09-29
IL201778A0 (en) 2010-06-16
ZA200908016B (en) 2012-04-25
BRPI0811210B1 (pt) 2021-11-09
US20100150843A1 (en) 2010-06-17
EP2146749A2 (en) 2010-01-27
CN101848734B (zh) 2013-08-28
WO2008139207A3 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
CA2685553C (en) Peptide imaging agents
US8431111B2 (en) Peptide imaging agents
AU2019246196B2 (en) Formulation and method of preparation
US20100303727A1 (en) Optical imaging agents
US20100196282A1 (en) Optical imaging agents
US20110268660A1 (en) Method for detecting dysplasia
WO2013045662A1 (en) Peptide margin imaging agents
WO2013045650A2 (en) Infusion imaging method
HK1148476A (en) Labelled hgf binding peptides for imaging
HK40047564B (en) Formulation and method of preparation
HK40047564A (en) Formulation and method of preparation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130416

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251110

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20251118

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260225